{"denoms":[{"counts":[{"groupId":"BG000","value":"483"},{"groupId":"BG001","value":"240"},{"groupId":"BG002","value":"723"}],"units":"Participants"}],"groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"BG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"BG001","title":"Arm B (Nab-Paclitaxel+Carboplatin)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.5","value":"63.8"},{"groupId":"BG001","spread":"8.9","value":"64.4"},{"groupId":"BG002","spread":"9.3","value":"64.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"308"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"277"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"415"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"37"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"426"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"639"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"47"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"17"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"26"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"428"},{"groupId":"BG001","value":"222"},{"groupId":"BG002","value":"650"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"28"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}